Naldemedine not checked

Shionogi

FollowEvery change as it happens, and a Monday email
Next date
Phase 1/2 trial completes
Trials
1 active
2 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)”In the company’s words, NCT05588323 on ClinicalTrials.gov
Tested for
Opioid-Induced Constipation (OIC)
Main trialPhase 1/2
“The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.”In the company’s words, NCT05588323 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 15 Jun 2028 Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
Phase 2Ended not given The effect of naldemedine on opioid-induced bowel dysfunction
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Naldemedine

Following is part of Solo: you see every change to Naldemedine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in